ArticleFrontiers in medicine2023
External validation of a convolutional neural network for the automatic segmentation of intraprostatic tumor lesions on
Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Artificial intelligence for radiopharmaceutical and molecular imaging.Acta pharmaceutica Sinica. B · 2025Review
- Integration of prostate-specific membrane antigen-PET and multiparametric MRI for gross tumour volume definition in localised and locally advanced prostate cancer treated with image-guided radiotherapy.Current opinion in urology · 2025Review
- A fully automated AI-based method for tumour detection and quantification on [EJNMMI physics · 2025Article
- AI-Guided Delineation of Gross Tumor Volume for Body Tumors: A Systematic Review.Diagnostics (Basel, Switzerland) · 2025Review
- The impact of multicentric datasets for the automated tumor delineation in primary prostate cancer using convolutional neural networks onRadiation oncology (London, England) · 2024Article
- Catalyzing Precision Medicine: Artificial Intelligence Advancements in Prostate Cancer Diagnosis and Management.Cancers · 2024Review
- The Application of Radiomics and AI to Molecular Imaging for Prostate Cancer.Journal of personalized medicine · 2024Review
- Machine Learning CT-Based Automatic Nodal Segmentation and PET Semi-Quantification of IntraoperativeDiagnostics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: State of the art artificial intelligence (AI) models have the potential to become a "one-stop shop" to improve diagnosis and prognosis in several oncological settings. The external validation of AI models on independent cohorts is essential to evaluate their generalization ability, hence their potential utility in clinical practice. In this study we tested on a large, separate cohort a recently proposed state-of-the-art convolutional neural network for the automatic segmentation of intraprostatic cancer lesions on PSMA PET images. Methods: Eighty-five biopsy proven prostate cancer patients who underwent Results: When compared to the manual contouring, the AI model yielded a median dice score = 0.74, therefore showing a moderately good performance. Results were robust to the modality used to acquire images (PET/CT or PET/MRI) and to the ground truth labels (no significant difference between the model's performance when compared to reader 1 or reader 2 manual contouring). Discussion: In conclusion, this AI model could be used to automatically segment intraprostatic cancer lesions for research purposes, as instance to define the volume of interest for radiomics or deep learning analysis. However, more robust performance is needed for the generation of AI-based decision support technologies to be proposed in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.